Global In-Vitro Diagnostics (IVD) Market to Reach USD 74.32 Billion by 2020
The global market for IVD is expected to reach USD 74.32 billion by 2020, according to a new study by Grand View Research, Inc. Constantly improving patient awareness levels pertaining to infectious diseases and their subsequent diagnosis, the introduction of advanced molecular and tissue diagnostic tests for cancer such as companion diagnostics and the growing global base of geriatric population are some of the primary drivers for this market. Moreover, rising global healthcare expenditures, especially in Asia Pacific and increasing demand for rapid, minimally invasive and non-invasive diagnostic procedures are also expected to have a positive impact on market growth. The emergence of epigenomics-based diagnostics and the ability of molecular diagnostics to detect disease at an early stage of development are expected to create opportunity for industry participants to capitalize on over the next six years.
The professional diagnostic products dominated the overall IVD market in 2013, owing to the high usage rates of these tests in diagnostic tests pertaining to the infectious disease segment, and are expected to grow at a CAGR of 4.7% from 2014 to 2020 to reach an estimated value of USD 49.76 billion by 2020. However, the tissue diagnostics market is expected to grow at the highest CAGR of 10.2% from 2014 to 2020, owing to its growing application in cancer diagnosis and need for lab automation as a consequence of limited skilled labor availability.
The report “In-Vitro Diagnostics (IVD) Market Analysis And Segment Forecasts To 2020,” is available now to Grand View Research customers at
Sample Report @ http://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-ivd-market/sample
Further Key findings from the study suggest:
• North America is expected to dominate the overall market throughout the forecast period, majorly on account of the presence of sophisticated healthcare infrastructure, high patient awareness levels and improving reimbursement frameworks, with revenue estimated to reach USD 28.79 billion by 2020.
• Asia Pacific is expected to be the fastest growing regional market for IVD, at an estimated CAGR of 7.4% from 2014 to 2020. The presence of high unmet medical needs for cancer and infectious diseases and a constantly improving healthcare infrastructure in emerging markets such as China and India are some of the drivers of this market.
• The global molecular diagnostics market is expected to follow the tissue diagnostics segment in terms of growth during the forecast period, owing to the growing demand for advanced genetic and HPV diagnostic tests. Its market is expected to grow at a CAGR of 8.7% from 2014 to 2020.
• Some of the key players of this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, bioMerieux, Beckman Coulter Inc., Becton Dickinson and others
About Grand View Research
Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit http://www.grandviewresearch.com
Corporate Sales Specialist, USA
Grand View Research, Inc
Toll Free: 1-888-202-9519
Releted Market Research Report:
Peripheral Vascular Devices Market Analysis By Product (Peripheral Vascular Stents, Peripheral Transluminal Angioplasty Balloon Catheters, PTA Guidewires, Atherectomy Devices, Chronic Total Occlusion Devices, Aortic Stents, Synthetic Surgical Grafts, Embolic Protection Devices & Inferior Vena Cava Filters) And Segment Forecasts To 2020 - http://www.grandviewresearch.com/industry-analysis/peripheral-vascular-devices-market
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.